

ERP assessed reproductive health medicines available for procurement

Last updated 04 April 2019

The ERP assesses the potential risks/benefits associated with the use of the medicines submitted and advises UNFPA on its decision on whether to procure these products. There are 4 different risk category ratings, where the first two, i.e. 1 and 2, are translated into non objection for procurement and the last two, 3 and 4, imply an objection for procurement. In the case of risk category 3 rating, procurement might be enabled in cases where the risk of no procurement outweighs the risk of procurement, as determined by the procurer.

The ERP risk rating of 1 or 2 for a reproductive health (RH) medicine translates into an ERP no-objection for procurement valid for 18 months; this means that the RH medicine can be supplied for this period. In certain cases, procurement period might be extended for 12 additional months after reassessment of a new submission of the product. The table below includes all the RH medicines comprised under risk category 1 and 2, and hence considered as an option for procurement.

Note: In case a client requires any other product that does not appear on this list please contact UNFPA QA at qa-team-group@unfpa.org so all the options for procurement can be considered depending on the situation.

Ref No	International Non-proprietary Name	Category	Formulation and strength	Shelf-life	Storage conditions	Pack size	Manufacturer	Country	Contact	Manufacturing site(s)	Date of inclusion of ERP	Date of end of validity of results
01	Medroxyprogesterone acetate	Injectable contraceptive	depot injection 150 mg/ml, in 1-ml vial	36 months	Do not store above 30°C. Do not freeze.	20 vials in a pack	PT TUNGGAL	Indonesia	Hendra Gunawan (Mr) hg@tia-pharma.com Rose Ernie Haryati (Mrs) rose@tia-pharma.com	Jl. Jendral Ahmad Yani No. 7 Jakarta Timur 13230 INDONESIA	Dec 2018	June 2020

All products procured based on ERP positive assessment will undergo pre-shipment quality control testing.